Heat Biologics, Inc. (HTBX)
| Market Cap | 187.70M |
| Revenue (ttm) | 4.34M |
| Net Income (ttm) | -22.93M |
| Shares Out | 20.53M |
| EPS (ttm) | -1.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $7.99 |
| Previous Close | $7.91 |
| Change ($) | 0.08 |
| Change (%) | 1.01% |
| Day's Open | 7.98 |
| Day's Range | 7.56 - 8.13 |
| Day's Volume | 524,387 |
| 52-Week Range | 1.44 - 30.10 |
Heat Biologics said Tuesday adding its experimental drug to Bristol Myers Squibb's Opdivo helped more lung-cancer patients survive. In response, HTBX stock catapulted.
Heat Biologics (HTBX) stock is heating up on Tuesday after revealing interim data from a Phase 2 trial of its lung cancer treatment. The post Heat Biologics News: Why HTBX Stock Is Going Gangb...
Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) O...
Heat Biologics: Investors Would Be Wise To Hold Off Until 2H 2021 Clinical Trial Interim Results
DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate ...
DURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate ...
DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate t...
Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Com...
Heat Biologics (HTBX) has announced details for a reverse stock split in order to keep shares of HTBX stock trading on the Nasdaq. The post Heat Biologics Reverse Stock Split: 10 Things for HT...
Heat Biologics boosts patents portfolio with gp96 combination award. Teleflex announces acquisition of hemostatic company Z-Medica.
Heat Biologics (HTBX) is in the news Thursday as HTBX stock takes a wild ride following an increasing focus on coronavirus stocks. The post Heat Biologics News: Why HTBX Stock Is On the Move T...
COVID-19 vaccine stocks have gotten slammed this month.
Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.
Encouraging early results for the biotech's coronavirus vaccine have investors excited.
Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.
The biotech's COVID-19 vaccine candidate hit the mark in a preclinical study.
Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.
The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been thi...
As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks t...
About HTBX
Heat Biologics, a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2013 |
| CEO Jeffrey Wolf | Employees 36 |
| Stock Exchange NASDAQ | Ticker Symbol HTBX |
Financial Performance
In 2019, Heat Biologics's revenue was $3.05 million, a decrease of -47.37% compared to the previous year's $5.79 million. Losses were -$20.02 million, 27.2% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for Heat Biologics stock is "Strong Buy." The 12-month stock price forecast is 29.25, which is an increase of 266.08% from the latest price.